Efficacy & safety of continuous erythropoietin receptor activator (CERA) in treating renal anaemia in diabetic patients with chronic kidney disease not on dialysis

BACKGROUND & OBJECTIVES: Chronic kidney disease (CKD) patients on dialysis regularly receive erythropoiesis stimulating agent (ESA) for treating renal anaemia during their dialysis unlike those who are not on dialysis. In such patients, the longer acting ESA can be helpful in reducing their freq...

Descripción completa

Detalles Bibliográficos
Autores principales: Vankar, Sameer G., Dutta, Pinaki, Kohli, H.S., Bhansali, Anil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994727/
https://www.ncbi.nlm.nih.gov/pubmed/24604046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994727/
https://www.ncbi.nlm.nih.gov/pubmed/24604046

Ejemplares similares